

Applicant : Alain Friboulet et al.
Serial No. : 10/716,030
Filed : November 17, 2003
Page : 2 of 5

Attorney's Docket No.: 16773-002001 / B4852AF-
AD/DBO/SZ

Amendments to the Specification:

Please insert the paper copy of the Sequence Listing filed herewith following the Drawings.

Replace the paragraph beginning at page 9, line 15 with the following rewritten paragraph:

In particular, a preferred compound is characterized in that it comprises a peptide derived from the cytokine TNF α , said compound being non immunogenic and having a specific affinity for the catalytic site of a catalytic antibody and said peptide contains one of the following amino acids sequences:

LNRRA (SEQ ID NO:1), IASVY (SEQ ID NO:2) or LFA.